Top Story

Application of whole blood before staining improves outcomes of macular hole surgery

August 23, 2016

Application of whole blood followed by brilliant blue staining of the internal limiting membrane allowed earlier and better visual rehabilitation in macular hole surgery than conventional brilliant blue staining, a study found.

“[This] could be attributed to earlier photoreceptor regeneration as evidenced by inner segment/outer segment junction continuity and increase in outer foveal thickness,” the study authors, from Guru Nanak Eye Centre in New Delhi, India, said.

Publication Exclusive: Good early results seen with pre-Descemet's endothelial keratoplasty in failed grafts

August 23, 2016
Graft failure in any situation can happen due to inherent defects in the donor graft or pre-existing pathology in the recipient. Inherent graft issues such as low…
From OSN Europe

Presbia completes purchase of Neoptics

August 23, 2016
Presbia Ireland Ltd., a wholly owned subsidiary of Presbia PLC, has purchased the assets of Neoptics AG. The purchase includes Neoptics’ intellectual property…
Meeting News CoverageVideo

VIDEO: Surgeon reviews pros and cons of prophylactic measures

August 23, 2016
At Hawaiian Eye, Terrence P. O'Brien, MD, relates the Bascom Palmer Eye Institute's experience with infection prevention measures in patients undergoing cataract surgery…

Publication Exclusive: Practice decline syndrome: Fighting the dwindles Practice Management

August 22, 2016
“There is at least one point in the history of any company when you have to change dramatically to rise to the next level of performance. Miss that moment —
More News Headlines »
Clinical Science

Hyperacuity Exam Screens for Choroidal Neovascularization in Age-Related Macular Degeneration on a Mobile Device

Ophthalmic Surgery, Lasers and Imaging Retina, August 2016, Volume 47 Issue 8
Timely treatment of age-related macular degeneration (AMD) is integral in improving outcomes. To catch choroidal…
More »

Imaging Modalities in Clinical Trials

This activity is supported by educational grants from Allergan, Inc.; Genentech, Inc.; and Regeneron Pharmaceuticals, Inc.

The advent of intravitreal therapies to treat retinal diseases has revolutionized the management of retinal pathology…
More »
Meeting News Coverage

VIDEO: Review finds no difference in anti-VEGF agents used for diabetic retinopathy

August 16, 2016
More »